CareOne Concierge began recruiting participants for a clinical trial of a non-invasive device intended to assist individuals with Alzheimer’s disease.
The trial will assess the safety and efficacy of the new therapeutic technology, which employs soft stimulation techniques meant to enhance cognitive performance. The program is part of an ongoing research effort to identify non-pharmacological treatments that can help individuals with Alzheimer’s in its early or moderate phases.
Health Technology Insights: Lustgarten Foundation Appoints Arthur Kuan, MS, to Board of Directors
Recruitment is possible among individuals aged 50 to 85 years who have been diagnosed with mild to moderate Alzheimer’s and fulfill other entrance criteria. The study will take place at several clinical sites, allowing participants to help advance care for dementia while being closely monitored by medical professionals.
“We all know friends and family members who have been impacted by Alzheimer’s or dementia,” said Peter Bechtel, CEO of CareONE Concierge. “This study represents a potential turning point in the fight against these devastating conditions. By participating in this study, individuals have the opportunity to experience cutting-edge, non-drug therapy while contributing to groundbreaking advancements in Alzheimer’s treatment.”
Health Technology Insights: Rhode Island Creates Rare Disease Advisory Council
Dr. Edward Goodwin, Chief Scientist at NeuroEM, emphasized the scientific foundation behind TEMT-RF, stating, “Our research has shown that TEMT-RF has the potential to impact the key biological processes associated with Alzheimer’s disease. This study will help us gather more real-world data on how the device affects cognitive function and overall brain health.”
The technology implemented in the study is not invasive and intended for home use, which makes it a user-friendly potential solution for patients and caregivers. The study also incorporates frequent cognitive testing and surveillance to monitor safety and obtain comprehensive feedback regarding users’ experiences. Participants who pass the initial screening will be provided with the device and appropriate support as part of their participation. To learn more or to apply to participate in the trial, individuals and families are invited to call CareOne Concierge directly. The program is an expanding interest in integrating technology and patient-centered care to treat complex neurological disorders with more compassion and accuracy.
“NeuroEM is excited to partner with CareONE Concierge,” stated Chuck Papageorgiou, CEO of NeuroEM Therapeutics. “Our objective is to promote safe, effective, and non-invasive technologies for cognitive health, and research initiatives like this are essential in helping us uncover the full potential of TEMT-RF. With Alzheimer’s cases increasing, innovative research such as this provides new hope for patients, caregivers, and the future of cognitive health. Together, we can take meaningful steps toward a future where memory loss is no longer an inevitable part of aging.”
Health Technology Insights: INOVIO Announces Pricing of $25 Million Public Offering
To participate in our interviews, please write to our HealthTech Media Room at sudipto@intentamplify.com
